Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Esomeprazole Magnesium Enteric Dry Suspension issued by the National Medical Products Administration. Esomeprazole is a proton pump inhibitor and the S-isomer of omeprazole. It specifically inhibits the H+-K+ ATPase in gastric parietal cells, blocking the final step of gastric acid secretion. Esomeprazole converts into its active form in the acidic environment of gastric parietal cells, effectively suppressing both basal and stimulated gastric acid secretion.
Comments